This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pembrolizumab for Stage IV Colorectal Carcinoma – first line

< Back

Pembrolizumab for Stage IV Colorectal Carcinoma – first line


Cancer and Palliative Care

June 2018

Colorectal or bowel cancer is a cancer that begins in the large bowel and is the fourth most common cancer in the UK. Metastatic/advanced colorectal cancer, or Stage IV, occurs when the cancer has spread to another part of the body; this is most commonly to the liver. A small proportion of colorectal cancer cases develop due to deficiencies in a repair mechanism for DNA; this may contribute to an increase in potential faulty (mutated) DNA. A high rate of this mutation is known as high microsatellite instability or mismatch repair deficient. These subsets of patients may have outcomes which are worse than those observed in the overall metastatic colorectal cancer population.
The most common treatment options for advanced colorectal cancer in the UK is surgery, radiotherapy and chemotherapy. Pembrolizumab is a type of immunotherapy that is delivered intravenously by a drip and that works by targeting specific proteins that stimulate an immune response attacking the cancer cells. It increases the body’s natural ability to identify and kill cancer cells. If licenced, pembrolizumab will offer an additional first line treatment option for patients with advanced colorectal cancer and prolong the time without cancer progression and overall survival.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts